Across TCGA pan-cancer cohorts, TRBV12-2 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated TRBV12-2 data layer.
The strongest signal is observed in testicular germ cell tumors (TGCT), where higher TRBV12-2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TRBV12-2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and PAAD show a favorable association.
TGCT, STAD, and LUSC are the cancer types where TRBV12-2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.